Sectoral Asset Management Inc. Lowers Position in Kura Oncology, Inc. $KURA

Sectoral Asset Management Inc. lowered its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 86.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,110 shares of the company’s stock after selling 341,762 shares during the period. Sectoral Asset Management Inc. owned approximately 0.06% of Kura Oncology worth $562,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its holdings in shares of Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Kura Oncology by 115.3% in the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after acquiring an additional 1,284 shares in the last quarter. Profund Advisors LLC raised its holdings in shares of Kura Oncology by 178.3% in the 4th quarter. Profund Advisors LLC now owns 69,124 shares of the company’s stock valued at $718,000 after acquiring an additional 44,289 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Kura Oncology by 10.0% in the 4th quarter. ProShare Advisors LLC now owns 18,572 shares of the company’s stock valued at $193,000 after acquiring an additional 1,692 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. UBS Group reissued a “buy” rating and set a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Wedbush decreased their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Mizuho decreased their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $26.38.

Kura Oncology Price Performance

Shares of KURA stock opened at $11.25 on Monday. The firm has a market cap of $998.66 million, a P/E ratio of -3.36 and a beta of 0.32. Kura Oncology, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.49. The business’s 50 day moving average price is $9.01 and its 200-day moving average price is $9.45. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.05. The firm had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. On average, equities research analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.